COVAXIN has demonstrated an interim vaccine efficacy of 81% in its Phase 3 clinical trial. The trials involved 25,800 subjects, the largest ever conducted in India, in partnership with ICMR: Bharat Biotech pic.twitter.com/jDIka9LIEE

— ANI (@ANI) March 3, 2021